Skip to Content

Join the 'Tardive Dyskinesia' group to help and get support from people like you.

Tardive Dyskinesia News

Related terms: Tardive, Dyskinesia

Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults

Posted 30 Aug 2017 by

JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. Austedo was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia i ...

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients

Posted 25 Aug 2017 by

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. ...

First Drug for Tardive Dyskinesia, Ingrezza (valbenazine), Approved

Posted 12 Apr 2017 by

WEDNESDAY, April 12, 2017 – Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration. The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and ...

Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)

Posted 11 Apr 2017 by

SAN DIEGO, April 11, 2017 /PRNewswire/ – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). Ingrezza, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first and only FDA-approved product indicated for the ...

Ask a Question

Further Information

Related Condition Support Groups

Extrapyramidal Reaction

Related Drug Support Groups

propranolol, clonidine, ropinirole, pramipexole, bromocriptine, vitamin e, chlordiazepoxide, Ingrezza, tetrabenazine, view more... Austedo, E-400 Clear, E-Gems, E-600, Aqua Gem-E, Aqua-E, Aquavite-E, apomorphine, Nutr-E-Sol, Alpha E, Vita-Plus E Natural, Amino-Opti-E, Aquasol E, valbenazine, deutetrabenazine, E Pherol